Dr Hannah King completed her PhD at the Burnet Institute in 2018, investigating the antigenicity and immunogenicity of novel HIV vaccine candidates. From there, she moved to the US for a postdoctoral appointment jointly between the National Institutes of Health and the U.S. Military HIV Research Program, focused on assessing the efficacy of HIV cure and vaccine strategies in non-human primate models. In 2024 she returned to Melbourne to take a position as a Research Officer in Sharon Lewin's lab, where she is investigating the immunological impacts of novel HIV cure interventions in clinical trials.
